Combination treatment for newly diagnosed acute monocytic leukemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effectiveness and side effects of a combination treatment using venetoclax, azacitidine, and chidamide for patients with newly diagnosed acute monocytic leukemia (AML-M5) who are not eligible for intensive chemotherapy. The approach aims to address the challenges posed by resistance to venetoclax due to high levels of the anti-apoptotic protein MCL1, which is prevalent in AML-M5. By incorporating chidamide, a selective histone deacetylase inhibitor, the study seeks to enhance the therapeutic efficacy of the treatment regimen. The trial will evaluate both the clinical outcomes and safety profiles of this novel combination therapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Confirmation of acute monocytic leukemia( AML-M5) diagnosis by the French-American-British (FAB) Classification and/or characterized for expression of monocytic and myeloid differentiation markers, have a projected life expectancy of at least 12 weeks, previously untreated, and ineligible for treatment with intensive chemotherapy.

Patients must be considered ineligible for induction therapy defined by the following:

1. \>= 60 years of age
2. \>=18 to 59years of age with at least one of the following comorbidities:

   Any other comorbidity that the physician judges to be incompatible with intensive chemotherapy:

   (A)Eastern Cooperative Oncology Group (ECOG) performance status of 2 or 3. (B)Cardiac history of congestive heart failure requiring treatment or ejection fraction \<= 50% or chronic stable angina.

   (C)Diffusing capacity of the lung for carbon monoxide (DLCO) \<= 65% or forced expiratory volume during the first second (FEV1) \<= 65%.

   (D)Creatinine clearance \>= 30 mL/min to \< 45 mL/min. (E)Moderate hepatic impairment with total bilirubin \> 1.5 to \<= 3.0 × upper limit of normal (ULN).
3. Must meet the laboratory requirements per the protocol.
4. Female participant must not be pregnant or breastfeeding and is not considering becoming pregnant or donating eggs during the study or for approximately 90 days after the last dose of study drug.
5. Female participants of childbearing potential must agree to use at least 1 protocol-specified method of birth control and male participants, if sexually active with female partner(s) of childbearing potential, must agree to practice the protocol-specified contraception.
6. Did not receive radiotherapy, chemotherapy, targeted therapy or hematopoietic stem cell transplantation within 4 weeks before enrollment;
7. Other comorbidities that are not suitable for intensive chemotherapy;
8. The patient refused to receive intensive chemotherapy;
9. Ability to understand and willing to sign the informed consent for this trial.

Exclusion Criteria:

1. Patients who are allergic to the study drug or drugs with similar chemical structures
2. Pregnant or lactating women, and women of childbearing age who do not want to practice effective methods of contraception
3. Active infection
4. Active bleeding
5. Patients with new thrombosis, embolism, cerebral hemorrhage, or other diseases or a medical history within one year before enrollment
6. Patients with mental disorders or other conditions whereby informed consent cannot be obtained and where the requirements of the study treatment and procedures cannot be met
7. Liver function abnormalities (total bilirubin \> 1.5 times the upper limit of the normal range, ALT/AST \> 2.5 times the upper limit of the normal range or patients with liver involvement whose ALT/AST \> 1.5 times the upper limit of the normal range), or renal anomalies (serum creatinine \> 1.5 times the upper limit of the normal value)
8. Patients with a history of clinically significant QTc interval prolongation (male \> 450 ms; female \> 470 ms), ventricular heart tachycardia and atrial fibrillation, II-degree heart block, myocardial infarction attack within one year before enrollment, and congestive heart failure, and patients with coronary heart disease who have clinical symptoms and requiring drug treatment
9. Urgery on the main organs within the past six weeks
10. Drug abuse or long-term alcohol abuse that would affect the evaluation results
11. Patients who have received organ transplants (excepting bone marrow transplantation)
12. Patients not suitable for the study according to the investigator's assessment

Where it's running

• The First Affliated Hospital of Soochow University
  Suzhou, Jiangsu, China Recruiting

Study contacts

• Study coordinator: Sheng-Li Xue, M. D.
• Email: slxue@suda.edu.cn
• Phone: 008651267781139

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Adding silibinin to standard daunorubicin or idarubicin therapy for newly diagnosed non‑M3 acute myeloid leukemia

  This trial will test whether adding silibinin (a liver‑protecting compound) to standard daunorubicin or idarubicin chemotherapy helps people with newly diagnosed non‑M3 acute myeloid leukemia.

  Recruiting Phase 4 Fujian Medical University Union Hospital · Fuzhou, Fujian · NCT07561892

• Venetoclax plus CACAG versus 3+7 for acute monocytic leukemia

  This trial will test whether adding venetoclax to a CACAG combination works better than standard 3+7 chemotherapy for people aged 14–60 with acute monocytic leukemia.

  Recruiting at 3 sites Phase 2 Chinese PLA General Hospital · Beijing and 2 other locations · NCT07512700

• Testing STX-0712 in patients with advanced blood cancers

  This study is testing a new drug called STX-0712 to see if it can help people with advanced blood cancers like chronic myelomonocytic leukemia and acute myeloid leukemia who have run out of other treatment options.

  Recruiting at 6 sites Phase 1 Solu Therapeutics, Inc · Stanford, California and 6 other locations · NCT06950034

• Combining Zanubrutinib and Obinutuzumab for Treating Newly Diagnosed Follicular Lymphoma

  This study is testing a new combination of two medications, Zanubrutinib and Obinutuzumab, to see if they can help people with newly diagnosed follicular lymphoma feel better and stay healthy.

  Recruiting Phase 2 The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT06553352

• Comparing different drug combinations for newly diagnosed acute myeloid leukemia

  This study is testing different combinations of drugs to see which one works best for people with newly diagnosed acute myeloid leukemia who can't handle strong chemotherapy.

  Recruiting Phase 2 The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT06532552

• Treatment for newly diagnosed monocytic acute myeloid leukemia using a combination of venetoclax and chemotherapy

  This study is testing a new treatment combining venetoclax and chemotherapy to see if it helps people with newly diagnosed monocytic acute myeloid leukemia feel better and live longer.

  Recruiting at 2 sites Phase 2 OHSU Knight Cancer Institute · Miami, Florida and 1 other locations · NCT06504459

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.